Clinical Trial

A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-16.
Status change: Not Yet Recruiting → Recruiting 2025-09-24
Trial Details
NCT Number NCT07036159
Lead Sponsor GlaxoSmithKline
Conditions Malaria
Enrollment 238 participants
Start Date 2025-08-06
Primary Completion 2027-04-23 (estimated)
Study Completion 2027-04-23 (estimated)
Updated on ClinicalTrials.gov 2025-09-29